
08/29/2025
🎓 Now available on demand:
Reimagining Management of Generalized Myasthenia Gravis: A Focus on FcRn Antagonists
In this CME webcast, expert faculty discuss how to:
✔ Evaluate the MOA, safety, and efficacy of FcRn antagonists
✔ Identify ideal candidates for FcRn therapy
✔ Develop individualized treatment plans
Watch now: https://cmeo.me/WCV-097
👩⚕️ Faculty: Dr. Christyn Edmundson | Dr. Neelam Goyal | Nichole VanElls, DNP
Generalized myasthenia gravis (gMG) is a chronic neuromuscular disorder that results from destruction of the neuromuscular junction by pathogenic autoantibodies, partially through the actions of the neonatal Fc receptor (FcRn). Traditional therapies only partially alleviate the...